News for Adyen N.V. (ADYEY)

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the Fund (Investor Shares) returned -8.59% (net of fees), outperforming the Russell 1000 Growth Index’s -9.97% decline. In the first quarter, post-election optimism, driven by […]

Adyen’s reset valuation, global growth, and strong fundamentals support double-digit returns despite risks like margin pressure. Read why ADYEY stock is a buy.

Pfizer's deep product pipeline, cost-cutting efforts, and dividend make the stock attractive. Adyen's shares look expensive for all the right reasons, and it should still deliver strong returns. Let's consider two stocks that are trading for less than $30 per share but are great picks for long-term investors: Pfizer (NYSE: PFE) and Adyen (OTC: ADYE.Y).

Here is how Adyen N.V. Unsponsored ADR (ADYEY) and Intuit (INTU) have performed compared to their sector so far this year.

Truist has begun covering Adyen (ADYEY) with a Buy rating and a target price of €1,875, reflecting confidence in the company's potential. Recognized as the le

Does Adyen N.V. Unsponsored ADR (ADYEY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Adyen N.V. (OTCPK:ADYEY) Q1 2025 Results Conference Call April 30, 2025 9:00 AM ETCompany ParticipantsMaggie O’Donnell - Investor RelationsEthan Tandowsky -...

Adyen reports a robust 22% increase in Q1 revenue, reaching $534.7 million. The average price target suggests a potential 23.69% upside from the current

Quick Summary: Adyen N.V.'s (ADYEY) stock has significantly declined over the past year. Wall Street analysts suggest a potential upside based on current

PayPal's transformation with AI, crypto, and more vs. Adyen's growth via smart payment routing. Click to find out which is a better bet among the digital payments platform.

Having significant capital in the bank when investing in equities is helpful, but is by no means necessary. If you're patient and hold on to it through the kind of market volatility we're experiencing, while occasionally purchasing more shares, that should result in excellent returns. Let's consider two great options: Pfizer (NYSE: PFE) and Adyen (OTC: ADYE.Y).

Redburn Atlantic has revised its price target for Adyen (ADYEY), lowering it from EUR 1,600 to EUR 1,550, while maintaining a Neutral rating on the stock. The f

Morgan Stanley has adjusted its price target for Adyen (ADYEY), reducing it slightly from EUR 2,150 to EUR 2,130. Despite this minor downgrade, the financial se

Generation Investment Management, an investment management firm, released its “Global Equity Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. The firm is not a momentum investor and avoids companies with uncertain future earnings and high valuations. The firm invests for the long-term and remains curious about new companies. […]

Generation Investment Management, an investment management firm, released its “Global Equity Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here.

Adyen's strong revenue growth, efficient operations, and strategic outlook promise robust returns. Find out why I assign ADYEY stock a Buy rating.

Here is how Adyen N.V. Unsponsored ADR (ADYEY) and Elastic (ESTC) have performed compared to their sector so far this year.

Stripe's growth is outpacing competitors, processing $1.4 trillion in volume last year, thanks in part to its role as the payment backbone for AI companies and focus on stablecoins.

Adyen (OTC: ADYE.Y) benefited tremendously from the COVID-19 pandemic, as digital payments activity took off. There are many companies all jockeying for a position to handle greater payment volume. Adyen might be unfamiliar because it focuses on targeting merchants rather than consumers.